3D Genomic Liquid Biopsy: Predictive, Prognostic & Diagnostic Biomarkers; From Immuno-Oncology to Early Screening of Populations at Risk
Time: 3:00 pm
day: Day 2 Track B PM
Details:
- EpiSwitch® 3D Genomic blood-based platform: from fundamental epigenetic biology to systemic clinical biomarkers for disease diagnosis, prognosis and prediction of treatment response;
- EpiSwitch CiRT (Checkpoint Inhibitor Response Test): Highly sensitive clinical blood test for prediction of systemic response to PD-1/-L1 immune checkpoint inhibitors;
- EpiSwitch PSE (Prostate Screening Test): novel, highly accurate, multivariant clinical blood test combining PSA with EpiSwitch biomarkers for a breakthrough in prostate cancer screening
